Q4 2025 Quest Diagnostics Inc Earnings Call Transcript
Key Points
- Quest Diagnostics Inc (DGX) achieved double-digit growth in revenues and earnings per share for the full year 2025.
- The company expanded its clinical innovations and formed strategic collaborations with elite healthcare organizations.
- Quest Diagnostics Inc (DGX) delivered high single-digit organic revenue growth in the physician channel and low single-digit growth in the hospital channel.
- The consumer-initiated testing platform, questhealth.com, exceeded a 20% revenue growth rate in 2025.
- The company achieved its full-year target of 3% annual cost savings and productivity improvements through the Invigorate program.
- The implementation of PAMA has been delayed, but structural flaws remain, potentially leading to future rate cuts.
- Operating income percent was reduced due to start-up expenses related to Fresenius Medical Care and Corewell Health, as well as Project Nova expenses.
- Severe weather in January 2026 created a headwind, impacting the first quarter's performance.
- The Corewell Health relationship is expected to add $250 million in organic revenue at low single-digit margins in 2026, impacting overall margin expansion.
- Project Nova is expected to result in approximately $0.25 of EPS dilution related to increased investment spend in 2026.
Welcome to the Quest Diagnostics fourth quarter and year-end 2025 conference call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and the question-and-answer session that will follow are the copyrighted property of Quest Diagnostics with all rights reserved.
Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited. Now I'd like to introduce Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics. Please go ahead.
Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer and President; and Sam Samad, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures.
We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
